(Q43795776)

26 November 2017

title

Miglitol combined with metformin improves glycaemic control in type 2 diabetes (English)

1 reference

26 November 2017

1 reference

1 reference

Van Gaal L

1

1 reference

26 November 2017

Maislos M

2

1 reference

26 November 2017

Schernthaner G

3

1 reference

26 November 2017

Rybka J

4

1 reference

26 November 2017

Segal P

5

1 reference

26 November 2017

publication date

1 October 2001

1 reference

Diabetes, Obesity and Metabolism

26 November 2017

published in

1 reference

26 November 2017

volume

3

1 reference

26 November 2017

issue

5

1 reference

26 November 2017

page(s)

326-331

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Acarbose: its role in the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Drug therapy of postprandial hyperglycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00141.X

10.1046/J.1463-1326.2001.00141.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference